Research programme: sirtuin activators - Sirtris

Drug Profile

Research programme: sirtuin activators - Sirtris

Alternative Names: SRT 1720; SRT 2172; SRT2183

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sirtris Pharmaceuticals
  • Developer Sirtris
  • Class Small molecules
  • Mechanism of Action SIRT1 protein stimulants; Sirtuin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Cancer; Chronic obstructive pulmonary disease; Huntington's disease; Inflammation; Neurological disorders; Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top